Investors – SynAct Pharma

A MESSAGE FROM OUR CEO

”It is exciting to see the company’s pipeline continue to advance and the business case around AP1189 strengthening.”

Press releases

November 4, 2022 Regulatory
SynAct Pharma publishes Q3 2022 interim report
November 1, 2022 Non Regulatory
SynAct Pharma receives IND clearance from the FDA for Phase 2a/b trial of AP1189 in RA

All press releases

Calendar

09

Jan

January 9 - January 12, 2023

J.P. Morgan Annual Health Care Conference
Add to calendar
17

Feb

February 17, 2023

Annual Results 2022
Add to calendar

All calendar events

Reports

November 4, 2022 Regulatory
SynAct Pharma publishes Q3 2022 interim report
August 5, 2022 Regulatory
SynAct Pharma publishes Q2 2022 interim report

All Reports

The share